8-KEarnings & ResultsExhibits & Filings

AbbVie Inc. 8-K Report, Financial Results (Jan 30, 2015)

Filed January 30, 2015For Securities:ABBV

Summary

This Form 8-K filing by AbbVie Inc. (ABBV) on January 30, 2015, primarily serves to furnish the company's earnings press release for the fourth quarter and full year 2014. While the 8-K itself does not contain detailed financial figures, it directs investors to the attached press release (Exhibit 99.1) for comprehensive information regarding the company's operational and financial performance during these periods. Investors should refer to the furnished press release for specific revenue, profit, and other key financial metrics that would inform their investment decisions. The filing indicates that AbbVie's Chief Financial Officer, William J. Chase, has signed off on the report, underscoring the official nature of the financial data being disseminated. The primary purpose of this filing is regulatory compliance, ensuring that material financial information is made public promptly. Investors seeking an in-depth understanding of AbbVie's 2014 performance and outlook should carefully review the content of the January 30, 2015 press release.

Key Highlights

  • 1AbbVie Inc. filed a Form 8-K on January 30, 2015.
  • 2The filing's primary purpose is to report the company's financial results for Q4 and full year 2014.
  • 3The detailed financial results are contained within an accompanying press release (Exhibit 99.1).
  • 4Investors are directed to the press release for operational and financial performance data.
  • 5The report is furnished under Item 2.02 (Results of Operations and Financial Condition).
  • 6The CFO, William J. Chase, is listed as signing the report.
  • 7The filing acts as a regulatory mechanism for disseminating material financial information.

Frequently Asked Questions

The main purpose of this Form 8-K filing is to officially report AbbVie Inc.'s financial results for the fourth quarter and the full fiscal year of 2014. It serves as a public announcement and regulatory filing for this important financial information.

The specific financial results, including revenue, earnings, and other key performance indicators for the fourth quarter and full year 2014, are detailed in the press release dated January 30, 2015, which is furnished as Exhibit 99.1 to this 8-K filing.

When an exhibit is 'furnished' as part of an 8-K, it means the document is being provided to the SEC for informational purposes, but it is not considered 'filed' in the same way as the main 8-K report. For investors, this means the press release contains the actual financial details and commentary that should be reviewed, rather than the brief 8-K form itself.

William J. Chase is listed as the Executive Vice President and Chief Financial Officer (CFO) of AbbVie Inc. His signature on the 8-K filing indicates his authorization and oversight of the reported financial information, lending official weight to the company's announcements.